Viatris Inc 8-K

What Happened

• On February 26, 2026, Viatris Inc. filed an 8-K and issued a press release reporting the company's financial results for the period ended December 31, 2025 and announcing 2026 guidance (Exhibit 99.1). The company also disclosed the results of an enterprise-wide strategic review (EWSR) begun in 2025 and committed to implementation of restructuring actions to reshape its commercial, R&D/medical/regulatory, and supply chain functions.

Key Details

• Viatris announced a global workforce reduction of up to approximately 10%.
• Expected total pre-tax restructuring charges: $700 million to $850 million.
  • Estimated non-cash portion: $50 million to $100 million (mainly accelerated depreciation and asset impairment, including inventory write-offs).
  • Estimated cash costs: $650 million to $750 million (primarily severance, employee benefits, contract terminations, vendor consolidations, product transfers, and network simplification/modernization).
• Management expects restructuring activities, costs, and associated savings to be completed primarily over the next three years.
• Projected annual run-rate savings once fully implemented: $600 million to $700 million, with most savings expected to improve operating cash flow.
• Viatris hosted a conference call and webcast on Feb 26, 2026 at 8:30 a.m. ET to review results. The filing includes standard forward-looking statement disclosures.

Why It Matters

• For investors, the announcement combines current financial reporting (Q4/FY2025 results and 2026 guidance) with a significant cost-reduction plan that will affect near-term earnings and cash outflows due to large one-time charges, while targeting substantial recurring savings that could boost future operating cash flow. The timeline—primarily over three years—means benefits and costs will be phased, so watch future quarterly filings for actual charge recognition, cash spend, and progress against the stated $600–700M in expected savings.